Article

Cannabinoids elicit antidepressant-like Behavior and activate Serotonergic neurons through the medial prefrontal cortex

Department of Psychiatry, McGill University, Montréal, Quebec, Canada
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.75). 11/2007; 27(43):11700-11. DOI: 10.1523/JNEUROSCI.1636-07.2007
Source: PubMed

ABSTRACT Preclinical and clinical studies show that cannabis modulates mood and possesses antidepressant-like properties, mediated by the agonistic activity of cannabinoids on central CB1 receptors (CB1Rs). The action of CB1R agonists on the serotonin (5-HT) system, the major transmitter system involved in mood control and implicated in the mechanism of action of antidepressants, remains however poorly understood. In this study, we demonstrated that, at low doses, the CB1R agonist WIN55,212-2 [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate] exerts potent antidepressant-like properties in the rat forced-swim test (FST). This effect is CB1R dependent because it was blocked by the CB1R antagonist rimonabant and is 5-HT mediated because it was abolished by pretreatment with the 5-HT-depleting agent parachlorophenylalanine. Then, using in vivo electrophysiology, we showed that low doses of WIN55,212-2 dose dependently enhanced dorsal raphe nucleus 5-HT neuronal activity through a CB1R-dependent mechanism. Conversely, high doses of WIN55,212-2 were ineffective in the FST and decreased 5-HT neuronal activity through a CB1R-independent mechanism. The CB1R agonist-induced enhancement of 5-HT neuronal activity was abolished by total or medial prefrontocortical, but not by lateral prefrontocortical, transection. Furthermore, 5-HT neuronal activity was enhanced by the local microinjection of WIN55,212-2 into the ventromedial prefrontal cortex (mPFCv) but not by the local microinjection of WIN55,212-2 into the lateral prefrontal cortex. Similarly, the microinjection of WIN55,212-2 into the mPFCv produced a CB1R-dependent antidepressant-like effect in the FST. These results demonstrate that CB1R agonists possess antidepressant-like properties and modulate 5-HT neuronal activity via the mPFCv.

0 Bookmarks
 · 
158 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZET: Tıbbi esrar psikiyatrik bozuklukların tedavisinde kullanılabilir mi? Esrar en yaygın ve en çok tüketilen yasadışı uyuşturucu maddedir. Esrarın bilinen uyuşturucu etkileri yanısıra bazı tıbbi hastalık belirtilerini düzeltmek için de kullanıldığı iddia edilmektedir. Son yıllarda esrarın kanser ve Edinilmiş Bağışıklık Yetersizliği Sendromu (AIDS) gibi bazı hastalıkla-ra bağlı aşırı kusma ve kilo kaybı durumları için tıbbi otori-telerden onay alması, esrarın bazı diğer hastalıklarda da kul-lanılabileceğini düşündürmektedir. Bu derlemede, esrarın bilimsel literatürde bildirilmiş olan bazı tıbbi kullanım alan-ları tartışılacak ve esrarın bazı psikiyatrik bozuklukların (ya da belirtilerinin) tedavisinde yardımcı olabilceğini bildiren iddialar bilimsel olarak gözden geçirilecektir. Bu sunumun esrar kullanımını yasallaştırmayı destekleme amacı yoktur. Anahtar sözcükler: Kannabis, kannabinoid sistem, tıbbi esrar, psikiyatrik bozukluklar Kli nik Psikofarmakoloji Bülteni 2012;22(1):98-109 ABS TRACT: Can medical marijuana be used in the treatment of psychiatric disorders? Cannabis is known to be the most commonly and most widely consumed illicit drug. Despite the known risks of cannabis use, there are anecdotal reports advocating that cannabis can be used in the treatment of or to correct the symptoms of some diseases. Since the approval of use of cannabis in some diseases such as AIDS, cancer, and extreme weight loss, it is suggested that cannabis may safely be used in the treatment of some other medical disorders. In this review, the medical use of cannabis in some medical conditions that were reported in the scientific literature will be reviewed and possible benefits of cannabis use in some psychiatric disorders (or symptoms) will be discussed. This presentation does not aim to support the legalization of cannabis use.
  • Source
    01/2011, Degree: BACHELOR OF MEDICAL AND HEALTH SCIENCES (HONOURS), Supervisor: Francesca Fernandez, Teresa Du bois
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression is one of the most frequent causes of disability in the 21st century. Despite the many preclinical and clinical studies that have addressed this brain disorder, the pathophysiology of depression is not well understood and the available antidepressant drugs are therapeutically inadequate in many patients. In recent years, the potential role of lipidderived molecules, particularly endocannabinoids (eCBs) and endovanilloids, has been highlighted in the pathogenesis of depression and in the action of antidepressants. There are many indications that the eCB/endovanilloid system is involved in the pathogenesis of depression, including the localization of receptors, modulation of monoaminergic transmission, inhibition of the stress axis and promotion of neuroplasticity in the brain. Preclinical pharmacological and genetic studies of eCBs in depression also suggest that facilitating the eCB system exerts antidepressant-like behavioral responses in rodents. In this article, we review the current knowledge of the role of the eCB/endovanilloid system in depression, as well as the effects of its ligands, models of depression and antidepressant drugs in preclinical and clinical settings.
    Journal of Applied Statistics 09/2014; 12(5). DOI:10.2174/1570159X12666140923205412 · 0.45 Impact Factor

Full-text

Download
48 Downloads
Available from
Jun 6, 2014